Co-administration of tariquidar using functionalized nanostructured lipid carriers overcomes resistance to docetaxel in multidrug resistant MCF7/ADR cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Chang Hyun | - |
dc.contributor.author | Lee, Tae Hwa | - |
dc.contributor.author | Kim, Byuong Deok | - |
dc.contributor.author | Kim, Hyeon Kyun | - |
dc.contributor.author | Lyu, Min Jeong | - |
dc.contributor.author | Jung, Hyun Min | - |
dc.contributor.author | Goo, Yoon Tae | - |
dc.contributor.author | Kang, Myung Joo | - |
dc.contributor.author | Lee, Sangkil | - |
dc.contributor.author | Choi, Young Wook | - |
dc.date.accessioned | 2022-05-04T02:40:14Z | - |
dc.date.available | 2022-05-04T02:40:14Z | - |
dc.date.issued | 2022-05 | - |
dc.identifier.issn | 1773-2247 | - |
dc.identifier.issn | 2588-8943 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57121 | - |
dc.description.abstract | To overcome multidrug resistance (MDR) and to enhance the efficacy of docetaxel (DTX), tariquidar (TRQ) was co-administered with DTX using nanostructured lipid carriers (NLC) functionalized with polyethylene glycol (PEG) and RIPL peptide (P/R). DTX- and TRQ-loaded plain NLC and P/R-NLC (P/R–N) were prepared using the solvent emulsification evaporation technique. All NLC samples showed a homogeneous spherical morphology and nano-sized dispersion (<210 nm) (zeta potential, −19 to −6 mV). DTX or TRQ was successfully encapsulated in NLC formulations (encapsulation efficiency >95%; drug loading 73–90 μg/mg). All NLC formulations were stable for 4 weeks when stored at 4 °C. Drug release was diffusion-controlled. DTX/TRQ combination at a 1:1 w/w ratio showed the highest synergism with a combination index value of 0.285 and was selected as the optimum combination. TRQ-P/R–N significantly enhanced the intracellular accumulation of Rhodamine 123 in MCF7/ADR cells. The co-administration of drug-loaded P/R-Ns led to potent and dose-dependent cytotoxicity and high MDR reversal efficiency. Co-treatment with DTX-P/R–N and TRQ-P/R–N increased apoptosis and enhanced G2/M cell cycle phase distribution in MCF7/ADR cells. These results indicate that the co-administration of DTX and TRQ using P/R-Ns may be a promising strategy to overcome MDR by P-gp inhibition in tumor treatments. © 2022 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Editions de Sante | - |
dc.title | Co-administration of tariquidar using functionalized nanostructured lipid carriers overcomes resistance to docetaxel in multidrug resistant MCF7/ADR cells | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.jddst.2022.103323 | - |
dc.identifier.bibliographicCitation | Journal of Drug Delivery Science and Technology, v.71 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000795541500003 | - |
dc.identifier.scopusid | 2-s2.0-85127669736 | - |
dc.citation.title | Journal of Drug Delivery Science and Technology | - |
dc.citation.volume | 71 | - |
dc.type.docType | Article | - |
dc.publisher.location | 네델란드 | - |
dc.subject.keywordAuthor | Co-administration | - |
dc.subject.keywordAuthor | Docetaxel | - |
dc.subject.keywordAuthor | Multidrug resistance | - |
dc.subject.keywordAuthor | Nanostructured lipid carriers | - |
dc.subject.keywordAuthor | P-gp inhibitor | - |
dc.subject.keywordAuthor | Tariquidar | - |
dc.subject.keywordPlus | CO-DELIVERY | - |
dc.subject.keywordPlus | DRUG-DELIVERY | - |
dc.subject.keywordPlus | NANOPARTICLES | - |
dc.subject.keywordPlus | PACLITAXEL | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | SYSTEMS | - |
dc.subject.keywordPlus | ACID | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.